Inflammation	O
-	O
modulating	O
effect	O
of	O
antithrombin	O
on	O
the	O
endothelium	B-Tissue
.	O

Ligation	O
of	O
heparan	O
sulfate	O
proteoglycans	O
(	O
HSPGs	O
)	O
of	O
endothelium	B-Tissue
with	O
antithrombin	O
(	O
AT	O
)	O
induces	O
cellular	B-Cell
signalling	O
events	O
that	O
alter	O
the	O
cell	B-Cell
'	O
s	O
biochemical	O
and	O
functional	O
responses	O
to	O
inflammatory	O
stimuli	O
(	O
e	O
.	O
g	O
.	O
bacterial	O
lipopolysaccharide	O
[	O
LPS	O
]	O
)	O
.	O

Changes	O
include	O
reduced	O
release	O
of	O
inflammatory	O
and	O
procoagulatory	O
mediators	O
(	O
e	O
.	O
g	O
.	O
interleukin	O
[	O
IL	O
]	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
[	O
TNF	O
]	O
)	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
and	O
cellular	B-Cell
adhesion	O
molecules	O
(	O
not	O
shown	O
)	O
,	O
as	O
well	O
as	O
increased	O
release	O
of	O
anticoagulatory	O
prostacyclin	O
(	O
prostaglandin	O
[	O
PG	O
]	O
I	O
)	O
or	O
CD39	O
/	O
ATPDase	O
.	O

In	O
neuronal	B-Tissue
tissue	I-Tissue
,	O
protective	O
mechanisms	O
may	O
by	O
mediated	O
via	O
the	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
and	O
nitric	O
oxide	O
with	O
the	O
potential	O
to	O
affect	O
prostacyclin	O
release	O
[	O
55	O
]	O
.	O

